Gain Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
GANX$1.08-0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year Ended December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| · · · · | ||||||
| Operating activities: · · · · | ||||||
| Net loss | | $(20,161,099) | | $(20,411,191) | ||
| | | | | | | |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | ||
| Depreciation and amortization | | 94,046 | | 84,071 | ||
| Stock-based compensation expense | | 1,803,195 | | 2,390,159 | ||
| Other non-cash items | | | 804,938 | | | 143,523 |
| | | | | | | |
| Changes in operating assets and liabilities: | | | | | ||
| Prepaid expenses and other current assets | | | (82,119) | | | (356,650) |
| Long term deposit and other noncurrent assets | | 2,852 | | (21,000) | ||
| Accounts payable and other current liabilities | | (468,606) | | 274,889 | ||
| Defined benefit pension plan | | | (130,568) | | | (122,915) |
| Deferred grant income | | (328,071) | | (854,713) | ||
| Total changes in operating assets and liabilities | | | (1,006,512) | | | (1,080,389) |
| Cash used in operating activities | | | (18,465,432) | | | (18,873,827) |
| | | | | | | |
| Cash flows from investing activities: | | | | | ||
| Purchase of property and equipment and internal-use software | | — | | (22,493) | ||
| Maturities of marketable securities | | | — | | | 5,000,000 |
| Cash provided by investing activities | | | — | | | 4,977,507 |
| | | | | | | |
| Cash flow from financing activities: | | | | | ||
| Net proceeds from issuance of shares in 2024 ATM Program (Note 14) | | 18,059,379 | | 2,951,133 | ||
| Net proceeds from issuance of shares in public offering (Note 14) | | 7,411,554 | | 10,261,178 | ||
| Net proceeds from the exercise of warrants (Note 14) | | | 3,218,552 | | | 113,800 |
| Net proceeds from the exercise of stock options (Note 15) | | | 250,260 | | | 57,711 |
| Payments of offering costs (Note 14) | | | (395,478) | | | (280,867) |
| Payments of current portion of long-term debt (Note 12) | | | (96,501) | | | (90,879) |
| Cash provided by financing activities | | | 28,447,766 | | | 13,012,076 |
| Effect of exchange rate changes | | | 474,032 | | | (527,168) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | | | 10,456,366 | | | (1,411,412) |
| Cash, cash equivalents and restricted cash at beginning of period | | 10,417,558 | | 11,828,970 | ||
| Cash, cash equivalents and restricted cash at end of period | | $20,873,924 | | $10,417,558 | ||
| | | | | | | |
| Supplemental Data: | | | | | | |
| Income taxes paid | | $47,549 | | $86,309 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.